182 related articles for article (PubMed ID: 25522951)
1. Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Pietzner K; Dietel M; Sehouli J; Darb-Esfahani S
Virchows Arch; 2015 Mar; 466(3):333-42. PubMed ID: 25522951
[TBL] [Abstract][Full Text] [Related]
2. CD56 (Neural Cell Adhesion Molecule) Expression in Ovarian Carcinomas: Association With High-Grade and Advanced Stage But Not With Neuroendocrine Differentiation.
Bösmüller HC; Wagner P; Pham DL; Fischer AK; Greif K; Beschorner C; Sipos B; Fend F; Staebler A
Int J Gynecol Cancer; 2017 Feb; 27(2):239-245. PubMed ID: 27984374
[TBL] [Abstract][Full Text] [Related]
3. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation in extrahepatic bile duct carcinomas and its prognostic significance.
Hong SM; Kim MJ; Pi DY; Jo D; Yu E; Ro JY
Hum Pathol; 2005 Jul; 36(7):732-40. PubMed ID: 16084941
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases.
Kendall Bártů M; Němejcová K; Michálková R; Bui QH; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Šafanda A; Singh N; Škapa P; Špůrková Z; Stolnicu S; Švajdler M; Lax SF; McCluggage WG; Dundr P
Int J Gynecol Pathol; 2024 Mar; 43(2):123-133. PubMed ID: 37406366
[TBL] [Abstract][Full Text] [Related]
6. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
7. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
[TBL] [Abstract][Full Text] [Related]
8. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
[TBL] [Abstract][Full Text] [Related]
9. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
[TBL] [Abstract][Full Text] [Related]
10. Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma.
Jakobsson ME; Moen A; Davidson B; Falnes PØ
PLoS One; 2015; 10(10):e0140168. PubMed ID: 26448330
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
12. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
13. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
[TBL] [Abstract][Full Text] [Related]
14. Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites.
Maelandsmo GM; Flørenes VA; Nguyen MT; Flatmark K; Davidson B
Tumour Biol; 2009; 30(1):15-25. PubMed ID: 19194111
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
[TBL] [Abstract][Full Text] [Related]
16. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium.
Tamura T; Jobo T; Watanabe J; Kanai T; Kuramoto H
Int J Gynecol Cancer; 2006; 16(2):821-6. PubMed ID: 16681768
[TBL] [Abstract][Full Text] [Related]
18. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
19. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
[TBL] [Abstract][Full Text] [Related]
20. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
